188 related articles for article (PubMed ID: 27796713)
1. Risk algorithms that include pathology adjustment for HER2 amplification need to make further downward adjustments in likelihood scores.
Evans DG; Woodward ER; Howell SJ; Verhoef S; Howell A; Lalloo F
Fam Cancer; 2017 Apr; 16(2):173-179. PubMed ID: 27796713
[TBL] [Abstract][Full Text] [Related]
2. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens.
Evans DG; Lalloo F; Howell S; Verhoef S; Woodward ER; Howell A
Breast Cancer Res Treat; 2016 Feb; 155(3):597-601. PubMed ID: 26888723
[TBL] [Abstract][Full Text] [Related]
3. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and characterization of BRCA1 and BRCA2 germline mutations in Chinese women with familial breast cancer.
Zhang J; Pei R; Pang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Breast Cancer Res Treat; 2012 Apr; 132(2):421-8. PubMed ID: 21614564
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
6. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
Guzmán-Arocho YD; Rosenberg SM; Garber JE; Vardeh H; Poorvu PD; Ruddy KJ; Kirkner G; Snow C; Tamimi RM; Peppercorn J; Schapira L; Borges VF; Come SE; Brachtel EF; Marotti JD; Warner E; Partridge AH; Collins LC
Br J Cancer; 2022 Feb; 126(2):302-309. PubMed ID: 34703009
[TBL] [Abstract][Full Text] [Related]
8. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
9. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting
Chew W; Moorakonda RB; Courtney E; Soh H; Li ST; Chen Y; Shaw T; Allen JC; Evans DGR; Ngeow J
J Med Genet; 2018 May; 55(5):344-350. PubMed ID: 29275357
[TBL] [Abstract][Full Text] [Related]
12. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
13. The spectrum of BRCA1 and BRCA2 mutations and clinicopathological characteristics in Chinese women with early-onset breast cancer.
Chen L; Fu F; Huang M; Lv J; Zhang W; Wang C
Breast Cancer Res Treat; 2020 Apr; 180(3):759-766. PubMed ID: 32072338
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
[TBL] [Abstract][Full Text] [Related]
15. Genetic testing in a cohort of young patients with HER2-amplified breast cancer.
Eccles DM; Li N; Handwerker R; Maishman T; Copson ER; Durcan LT; Gerty SM; Jones L; Evans DG; Haywood L; Campbell I
Ann Oncol; 2016 Mar; 27(3):467-73. PubMed ID: 26681682
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
[TBL] [Abstract][Full Text] [Related]
17. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
18. Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
Shimada S; Yoshida R; Nakashima E; Kitagawa D; Gomi N; Horii R; Takeuchi S; Ashihara Y; Kita M; Akiyama F; Ohno S; Saito M; Arai M
Breast Cancer; 2019 Nov; 26(6):846-851. PubMed ID: 30980249
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania.
Janavičius R; Rudaitis V; Mickys U; Elsakov P; Griškevičius L
Cancer Genet; 2014 May; 207(5):195-205. PubMed ID: 25066507
[TBL] [Abstract][Full Text] [Related]
20. Real-world multi-country study of
Lux MP; Lewis K; Rider A; Niyazov A
Future Oncol; 2022 Mar; 18(9):1089-1101. PubMed ID: 35098723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]